ACE2 and COVID-19: The study proved that ACE2‐Fc effectively blocked the entry of SARS‐CoV‐2 spike‐expressing pseudotyped virus into lung organoids, thus suppressing viral replication, suggesting that ACE2‐Fc provides a latent prospect for COVID‐19 treatment.